Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl
Cold Spring Harbor Perspectives in Medicine · 2023-05 · 13 (5) · a041307
DOI: 10.1101/cshperspect.a041307 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cold Spring Harbor Perspectives in Medicine, online erschienen am 27.09.2022. Verfasst von Jean Bennett und 1 weiteren Autor:innen. Beteiligte Einrichtung: Scheie Eye Institute at the Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania 19104, USA jebennet@pennmedicine.upenn.edu. Hauptthemen laut MEDLINE: Retinal Dystrophies. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Scheie Eye Institute at the Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania 19104, USA jebennet@pennmedicine.upenn.edu.
- Center for Advanced Retinal and Ocular Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, USA.
- Scheie Eye Institute at the Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania 19104, USA.
- Division of Ophthalmology at the Children's Hospital of Philadelphia of the Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania 19102, USA.
Zitieren
APA
Bennett, J., & Maguire, A. M. (2023). Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl. Cold Spring Harbor Perspectives in Medicine, 13(5), a041307. https://doi.org/10.1101/cshperspect.a041307
Vancouver
Bennett J, Maguire AM. Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl. Cold Spring Harbor Perspectives in Medicine. 2023;13(5):a041307. doi:10.1101/cshperspect.a041307
BibTeX
@article{Bennett2023,
author = {Bennett, Jean and Maguire, Albert M},
title = {Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl},
journal = {Cold Spring Harbor Perspectives in Medicine},
year = {2023},
volume = {13},
number = {5},
pages = {a041307},
doi = {10.1101/cshperspect.a041307}
}
EUVIMED